Mineralys Therapeutics, Inc. (MLYS)
(Real Time Quote from BATS)
$13.92 USD
+0.22 (1.61%)
Updated Oct 16, 2024 03:44 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MLYS 13.92 +0.22(1.61%)
Will MLYS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MLYS
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares
Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference